ADAR1 Capital Management, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 18, 2026), ADAR1 Capital Management, LLC reported 290 stock positions worth $1.6 billion. Its top holding was Abivax SA-ADR (ABVX) at 9.4% of the portfolio, followed by Protagonist Therapeutics (PTGX, 6.4%) and Roivant Sciences (ROIV, 5.5%). Compared with Q4 2025, it opened 71 new positions, sold out of 29, added to 98 and reduced 59. The biggest buy was Denali Therapeutics (DNLI, shares +3491%) and the biggest sale an exit from Avidity Biosciences (RNAM).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001940272
- Portfolio Value
- $1.6B (Q1 2026)
- SEC Filing
- 0001940272-26-000005 ↗ filed May 18, 2026
Holdings Value
Holdings 290 stocks · $1.6B
| ABVX Abivax SA-ADR | 9.41% | 1,394,019 | $155.2M | Add +5.8% |
| PTGX Protagonist Therapeutics Inc. | 6.35% | 994,119 | $104.8M | Reduce -5.3% |
| ROIV Roivant Sciences Ltd. | 5.52% | 3,285,906 | $91.0M | Reduce -4.2% |
| IMVT Immunovant Inc. | 4.03% | 2,679,010 | $66.5M | Add +8.0% |
| SPY SS SPDR S&P 500 ETF Trust-US | 2.99% | 75,940 | $49.4M | Add +38.9% |
| TERN Terns Pharmaceuticals Inc. | 2.92% | 914,699 | $48.2M | Add +68.9% |
| CYTK Cytokinetics Inc. | 2.53% | 632,556 | $41.7M | Add +17.1% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.51% | 1,139,331 | $41.4M | Add +268.3% |
| BOXX Alpha Architect 1-3 MNTH Box | 2.38% | 337,125 | $39.2M | No change |
| DNLI Denali Therapeutics Inc. | 2.18% | 1,871,455 | $35.9M | Add +3490.9% |
| BEAM Beam Therapeutics Inc. | 2.09% | 1,446,375 | $34.5M | New |
| ZLAB Zai Lab Ltd.-ADR | 1.63% | 1,425,367 | $26.8M | Add +14.3% |
| SEPN Septerna Inc. | 1.59% | 1,089,818 | $26.2M | Reduce -5.9% |
| VIR Vir Biotechnology Inc. | 1.49% | 2,744,714 | $24.6M | New |
| DBVT DBV Technologies SA-Spon ADR | 1.28% | 1,012,866 | $21.2M | New |
| AVR Anteris Technologies Global | 1.27% | 3,789,132 | $21.0M | Add +205.9% |
| INSP Inspire Medical Systems Inc. | 1.27% | 405,197 | $20.9M | Add +2601.3% |
| SRRK Scholar Rock Holding Corp. | 1.21% | 407,273 | $20.0M | Add +485.3% |
| RYTM Rhythm Pharmaceuticals Inc. | 1.11% | 211,450 | $18.4M | Add +311.8% |
| SYRE Spyre Therapeutics Inc. | 1.03% | 338,323 | $17.1M | Add +893.6% |
| CTMX Cytomx Therapeutics Inc. | 0.97% | 3,410,190 | $16.0M | Reduce -18.5% |
| PRTA Prothena Corp. PLC | 0.93% | 1,581,443 | $15.4M | Add +8.5% |
| SNY Sanofi-ADR | 0.93% | 316,939 | $15.3M | Add +399.3% |
| PCVX Vaxcyte Inc. | 0.91% | 259,137 | $15.1M | Reduce -17.9% |
| MNPR Monopar Therapeutics Inc. | 0.88% | 264,278 | $14.5M | Add +13.0% |
| ABUS Arbutus Biopharma Corp. | 0.85% | 3,133,175 | $14.1M | Reduce -42.1% |
| AMLX Amylyx Pharmaceuticals Inc. | 0.84% | 1,000,604 | $13.9M | Add +12.4% |
| CLDX Celldex Therapeutics Inc. | 0.82% | 427,816 | $13.6M | Reduce -33.9% |
| TSHA Taysha Gene Therapies Inc. | 0.81% | 2,979,429 | $13.3M | Add +19.4% |
| XENE Xenon Pharmaceuticals Inc. | 0.81% | 228,899 | $13.3M | Add +12.2% |
| STRO Sutro Biopharma Inc. | 0.79% | 524,441 | $13.1M | Add +681.9% |
| RVMD Revolution Medicines Inc. | 0.79% | 133,893 | $13.0M | Reduce -7.7% |
| ELVN Enliven Therapeutics Inc. | 0.78% | 329,540 | $12.9M | Add +998.5% |
| CGON CG Oncology Inc. | 0.76% | 185,699 | $12.6M | Reduce -28.1% |
| BIL SS SPDR BB 1-3M T-Bill ETF | 0.75% | 135,585 | $12.4M | No change |
| ESTA Establishment Labs Holdings | 0.73% | 213,473 | $12.1M | Add +24.5% |
| REPL Replimune Group Inc. | 0.73% | 1,582,987 | $12.1M | Add +27.5% |
| IVA Inventiva SA - ADR | 0.73% | 2,174,398 | $12.1M | Reduce -19.8% |
| IONS Ionis Pharmaceuticals Inc. | 0.73% | 160,338 | $12.0M | Add +9.0% |
| NKTR Nektar Therapeutics | 0.70% | 161,252 | $11.6M | Add +123.9% |
| IKT Inhibikase Therapeutics Inc. | 0.67% | 6,606,572 | $11.1M | Reduce -18.1% |
| SPRY Ars Pharmaceuticals Inc. | 0.66% | 1,361,536 | $10.9M | Add +268.4% |
| HLXC Helix Acquisition Corp. Class A | 0.62% | 1,000,000 | $10.3M | New |
| OVID Ovid Therapeutics Inc. | 0.61% | 4,544,113 | $10.1M | Add +6.0% |
| OKUR Onkure Therapeutics Inc. Class A | 0.61% | 2,434,941 | $10.1M | Add +140.1% |
| REGN Regeneron Pharmaceuticals | 0.57% | 12,154 | $9.4M | Add +0.8% |
| MLTX Moonlake Immunotherapeutics | 0.52% | 457,137 | $8.5M | New |
| LXEO Lexeo Therapeutics Inc. | 0.51% | 1,467,350 | $8.4M | Add +5.3% |
| IRD Opus Genetics Inc. | 0.51% | 1,849,004 | $8.4M | Add +4522.5% |
| TEVA Teva Pharmaceutical-SP ADR | 0.49% | 268,391 | $8.1M | Add +13.7% |
| SVRA Savara Inc. | 0.48% | 1,464,535 | $8.0M | Add +4.2% |
| MPLT Maplight Therapeutics Inc. | 0.46% | 374,909 | $7.6M | New |
| LONA Leonabio Inc. | 0.45% | 727,481 | $7.5M | Add +84.8% |
| EQ Equillium Inc. | 0.45% | 3,726,659 | $7.5M | Reduce -33.5% |
| VKTX Viking Therapeutics Inc. | 0.45% | 227,717 | $7.4M | Add +759.5% |
| DMRA Damora Therapeutics Inc. | 0.44% | 279,000 | $7.2M | New |
| URGN Urogen Pharma Ltd. | 0.43% | 395,459 | $7.1M | Add +215.4% |
| BBIO Bridgebio Pharma Inc. | 0.42% | 94,292 | $7.0M | Reduce -55.8% |
| PRME Prime Medicine Inc. | 0.42% | 1,973,282 | $6.9M | New |
| VRTX Vertex Pharmaceuticals Inc. | 0.41% | 15,075 | $6.7M | Add +9.9% |
| KRRO Korro Bio Inc. | 0.37% | 540,054 | $6.1M | New |
| VRDN Viridian Therapeutics Inc. | 0.36% | 304,422 | $6.0M | Add +294.3% |
| DHR Danaher Corp. | 0.36% | 30,932 | $5.9M | Add +20.8% |
| INSM Insmed Inc. | 0.35% | 35,392 | $5.8M | New |
| ASND Ascendis Pharma A/S | 0.35% | 25,014 | $5.7M | Reduce -1.2% |
| BHF Brighthouse Financial Inc. | 0.35% | 95,523 | $5.7M | No change |
| SRPT Sarepta Therapeutics Inc. | 0.35% | 262,058 | $5.7M | Add +807.8% |
| OACCU Oaktree Acquisition III Life | 0.33% | 516,482 | $5.5M | No change |
| FRNM Freenome Inc. filed as PERCEPTIVE CAP SOLUTIONS COR | 0.33% | 499,581 | $5.5M | Add +9.4% |
| KRYS Krystal Biotech Inc. | 0.31% | 20,014 | $5.2M | No change |
| ABOS Acumen Pharmaceuticals Inc. | 0.31% | 2,156,334 | $5.1M | Add +142.0% |
| IVVD Invivyd Inc. | 0.30% | 3,822,427 | $5.0M | Reduce -2.0% |
| BHAVU Bhav Acquisition Corp. | 0.30% | 495,000 | $4.9M | New |
| TARA Protara Therapeutic Inc. | 0.30% | 940,512 | $4.9M | Reduce -17.3% |
| AGIO Agios Pharmaceuticals Inc. | 0.29% | 140,672 | $4.8M | Reduce -25.2% |
| LLY Eli Lilly & Co. | 0.28% | 5,060 | $4.7M | New |
| DNTH Dianthus Therapeutics Inc. | 0.28% | 55,000 | $4.6M | New |
| ARWR Arrowhead Pharmaceuticals Inc. | 0.27% | 70,300 | $4.4M | Add +20.8% |
| BLTE Belite Bio Inc. - ADR | 0.26% | 26,880 | $4.3M | Reduce -32.5% |
| EVMN Evommune Inc. | 0.26% | 184,062 | $4.2M | No change |
| MLYS Mineralys Therapeutics Inc. | 0.25% | 154,686 | $4.2M | Add +13.6% |
| JANX Janux Therapeutics Inc. | 0.25% | 298,546 | $4.1M | Add +21.6% |
| CLYM Climb Bio Inc. | 0.25% | 597,662 | $4.1M | Reduce -58.3% |
| PALI Palisade Bio Inc. | 0.24% | 2,264,845 | $4.0M | Add +13.0% |
| AEXA American Exceptionalism Class A | 0.23% | 357,539 | $3.9M | No change |
| SPRB Spruce Biosciences Inc. | 0.23% | 58,600 | $3.8M | Add +1.0% |
| NAMS Newamsterdam Pharma Co. NV | 0.23% | 118,623 | $3.8M | No change |
| ZURA Zura Bio Ltd. | 0.23% | 630,403 | $3.8M | Add +12.2% |
| ACLX Arcellx Inc. | 0.22% | 32,084 | $3.7M | Add +1.9% |
| CTNM Contineum Therapeutics Inc. Class A | 0.22% | 276,661 | $3.6M | Reduce -0.8% |
| GLUE Monte Rosa Therapeutics Inc. | 0.22% | 215,752 | $3.5M | No change |
| ONC Beone Medicines Ltd.-ADR | 0.21% | 11,701 | $3.5M | New |
| TENX Tenax Therapeutics Inc. | 0.21% | 213,462 | $3.4M | Add +235.3% |
| AVBP Arrivent Biopharma Inc. | 0.20% | 141,814 | $3.3M | New |
| PLRX Pliant Therapeutics Inc. | 0.20% | 2,585,126 | $3.3M | Add +3402.0% |
| ATAI Ataibeckley Inc. | 0.20% | 913,242 | $3.2M | No change |
| RLMD Relmada Therapeutics Inc. | 0.19% | 451,918 | $3.1M | Add +1364.1% |
| CATX Perspective Therapeutics Inc. | 0.19% | 749,335 | $3.1M | Add +687.2% |
| CRBP Corbus Pharmaceuticals Holdi | 0.19% | 331,781 | $3.1M | Add +15.7% |
| ELDN Eledon Pharmaceuticals Inc. | 0.18% | 974,421 | $3.0M | Reduce -46.5% |
Options reported separately and not counted above: TERN calls ($10.5M), IWM puts ($6.8M), ABVX calls ($4.9M), LQDA puts ($3.8M), XBI puts ($1.9M), QURE calls ($1.6M), KPTI calls ($1.1M), KVACF calls ($900K), REPL calls ($765K), GUTS calls ($654K), NVO calls ($478K), RARE calls ($419K), and 4 more.
Other holdings (4): bonds, preferreds, convertibles and warrants · $8.6M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | 45,000 | $4.9M | New |
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | 20,000 | $3.6M | New |
| BRIDGEBIO PHARMA INC (BBIO 1.75 03/01/31) | NOTE 1.750% 3/0 · principal | 30,000 | $49K | New |
| ASPCR A Spac III Acquisition Corp. | RIGHT 01/02/2026 | 215,000 | $42K | No change |
Total filed on the 13F, all lines: $1.7B.
Portfolio Sells Q4 2025 → Q1 2026
| RNAM Avidity Biosciences Inc. | Sold out | 0.00% | −2.95 |
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −1.29 |
| ABUS Arbutus Biopharma Corp. | Reduce -42.1% | 0.85% | −1.09 |
| FULC Fulcrum Therapeutics Inc. | Reduce -89.6% | 0.06% | −1.00 |
| CDTX Cidara Therapeutics Inc. | Sold out | 0.00% | −0.99 |
| SEPN Septerna Inc. | Reduce -5.9% | 1.59% | −0.83 |
| BBIO Bridgebio Pharma Inc. | Reduce -55.8% | 0.42% | −0.80 |
| TFX Teleflex Inc. | Reduce -73.7% | 0.15% | −0.58 |
| IKT Inhibikase Therapeutics Inc. | Reduce -18.1% | 0.67% | −0.56 |
| PTGX Protagonist Therapeutics Inc. | Reduce -5.3% | 6.35% | −0.50 |
| CLDX Celldex Therapeutics Inc. | Reduce -33.9% | 0.82% | −0.49 |
| CBIO Crescent Biopharma Inc. | Reduce -91.7% | 0.06% | −0.48 |
| MAZE Maze Therapeutics Inc. | Reduce -72.1% | 0.09% | −0.47 |
| AAM Aa Mission Acquisition Cor-A | Sold out | 0.00% | −0.46 |
| IVVD Invivyd Inc. | Reduce -2.0% | 0.30% | −0.42 |
| CTMX Cytomx Therapeutics Inc. | Reduce -18.5% | 0.97% | −0.36 |
| QURE Uniqure NV | Reduce -67.6% | 0.08% | −0.35 |
| AVDL Avadel Pharmaceuticals Ltd. | Sold out | 0.00% | −0.24 |
| IWM iShares Russell 2000 ETF | Sold out | 0.00% | −0.22 |
| BLTE Belite Bio Inc. - ADR | Reduce -32.5% | 0.26% | −0.22 |
| BBOT Bridgebio Oncology Therapeut | Sold out | 0.00% | −0.21 |
| IVA Inventiva SA - ADR | Reduce -19.8% | 0.73% | −0.21 |
| EQ Equillium Inc. | Reduce -33.5% | 0.45% | −0.20 |
| BIIB Biogen Inc. | Reduce -54.7% | 0.12% | −0.20 |
| DVAX Dynavax Technologies Corp. | Sold out | 0.00% | −0.20 |
| CRVS Corvus Pharmaceuticals Inc. | Reduce -81.1% | 0.08% | −0.19 |
| CLYM Climb Bio Inc. | Reduce -58.3% | 0.25% | −0.18 |
| PCVX Vaxcyte Inc. | Reduce -17.9% | 0.91% | −0.18 |
| ATXS Astria Therapeutics Inc. | Sold out | 0.00% | −0.17 |
| GRCE Grace Therapeutics Inc. | Sold out | 0.00% | −0.17 |
| TARA Protara Therapeutic Inc. | Reduce -17.3% | 0.30% | −0.16 |
| OLMA Olema Pharmaceuticals Inc. | Sold out | 0.00% | −0.15 |
| ENGN Engene Holdings Inc. | Reduce -56.0% | 0.06% | −0.15 |
| HELP Cybin Inc. | Reduce -86.9% | 0.01% | −0.14 |
| RGNX Regenxbio Inc. | Reduce -69.3% | 0.02% | −0.13 |
| ACRS Aclaris Therapeutics Inc. | Reduce -78.4% | 0.03% | −0.11 |
| AGIO Agios Pharmaceuticals Inc. | Reduce -25.2% | 0.29% | −0.09 |
| INFQ Infleqtion Inc. | Sold out | 0.00% | −0.08 |
| RVMD Revolution Medicines Inc. | Reduce -7.7% | 0.79% | −0.07 |
| UTHR United Therapeutics Corp. | Sold out | 0.00% | −0.07 |
| JAZZ Jazz Pharmaceuticals PLC | Reduce -62.5% | 0.03% | −0.07 |
| PLYM Plymouth Industrial REIT Inc. | Sold out | 0.00% | −0.07 |
| QNRX Quoin Pharmaceuticals LT-ADR | Sold out | 0.00% | −0.06 |
| AZN Astrazeneca PLC-Spons ADR | Sold out | 0.00% | −0.06 |
| ACET Adicet Bio Inc. | Reduce -58.2% | 0.02% | −0.06 |
| ASND Ascendis Pharma A/S | Reduce -1.2% | 0.35% | −0.06 |
| VTYX Ventyx Biosciences Inc. | Sold out | 0.00% | −0.06 |
| MRK Merck & Co. Inc. | Reduce -67.4% | 0.02% | −0.05 |
| NRIX Nurix Therapeutics Inc. | Reduce -22.2% | 0.05% | −0.05 |
| ROIV Roivant Sciences Ltd. | Reduce -4.2% | 5.52% | −0.05 |
Portfolio Buys Q4 2025 → Q1 2026
| DNLI Denali Therapeutics Inc. | Add +3490.9% | 2.18% | +2.11 |
| BEAM Beam Therapeutics Inc. | New | 2.09% | +2.09 |
| VIR Vir Biotechnology Inc. | New | 1.49% | +1.49 |
| CRNX Crinetics Pharmaceuticals Inc. | Add +268.3% | 2.51% | +1.43 |
| TERN Terns Pharmaceuticals Inc. | Add +68.9% | 2.92% | +1.29 |
| DBVT DBV Technologies SA-Spon ADR | New | 1.28% | +1.28 |
| INSP Inspire Medical Systems Inc. | Add +2601.3% | 1.27% | +1.16 |
| SRRK Scholar Rock Holding Corp. | Add +485.3% | 1.21% | +0.98 |
| SYRE Spyre Therapeutics Inc. | Add +893.6% | 1.03% | +0.95 |
| AVR Anteris Technologies Global | Add +205.9% | 1.27% | +0.81 |
| ELVN Enliven Therapeutics Inc. | Add +998.5% | 0.78% | +0.75 |
| STRO Sutro Biopharma Inc. | Add +681.9% | 0.79% | +0.73 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +311.8% | 1.11% | +0.70 |
| SNY Sanofi-ADR | Add +399.3% | 0.93% | +0.70 |
| HLXC Helix Acquisition Corp. Class A | New | 0.62% | +0.62 |
| MLTX Moonlake Immunotherapeutics | New | 0.52% | +0.52 |
| IRD Opus Genetics Inc. | Add +4522.5% | 0.51% | +0.50 |
| NKTR Nektar Therapeutics | Add +123.9% | 0.70% | +0.48 |
| MPLT Maplight Therapeutics Inc. | New | 0.46% | +0.46 |
| DMRA Damora Therapeutics Inc. | New | 0.44% | +0.44 |
| PRME Prime Medicine Inc. | New | 0.42% | +0.42 |
| OKUR Onkure Therapeutics Inc. Class A | Add +140.1% | 0.61% | +0.39 |
| VKTX Viking Therapeutics Inc. | Add +759.5% | 0.45% | +0.38 |
| KRRO Korro Bio Inc. | New | 0.37% | +0.37 |
| INSM Insmed Inc. | New | 0.35% | +0.35 |
| SPRY Ars Pharmaceuticals Inc. | Add +268.4% | 0.66% | +0.34 |
| SRPT Sarepta Therapeutics Inc. | Add +807.8% | 0.35% | +0.30 |
| BHAVU Bhav Acquisition Corp. | New | 0.30% | +0.30 |
| LLY Eli Lilly & Co. | New | 0.28% | +0.28 |
| DNTH Dianthus Therapeutics Inc. | New | 0.28% | +0.28 |
| LONA Leonabio Inc. | Add +84.8% | 0.45% | +0.24 |
| URGN Urogen Pharma Ltd. | Add +215.4% | 0.43% | +0.21 |
| ONC Beone Medicines Ltd.-ADR | New | 0.21% | +0.21 |
| SPY SS SPDR S&P 500 ETF Trust-US | Add +38.9% | 2.99% | +0.20 |
| AVBP Arrivent Biopharma Inc. | New | 0.20% | +0.20 |
| PLRX Pliant Therapeutics Inc. | Add +3402.0% | 0.20% | +0.19 |
| VRDN Viridian Therapeutics Inc. | Add +294.3% | 0.36% | +0.18 |
| RLMD Relmada Therapeutics Inc. | Add +1364.1% | 0.19% | +0.18 |
| CATX Perspective Therapeutics Inc. | Add +687.2% | 0.19% | +0.17 |
| ABOS Acumen Pharmaceuticals Inc. | Add +142.0% | 0.31% | +0.17 |
| CAPR Capricor Therapeutics Inc. | New | 0.17% | +0.17 |
| PEPG Pepgen Inc. | Add +4263.6% | 0.17% | +0.15 |
| TENX Tenax Therapeutics Inc. | Add +235.3% | 0.21% | +0.15 |
| APLS Apellis Pharmaceuticals Inc. | Add +262.5% | 0.18% | +0.14 |
| DRUG Bright Minds Biosciences Inc. | Add +868.6% | 0.15% | +0.13 |
| XENE Xenon Pharmaceuticals Inc. | Add +12.2% | 0.81% | +0.12 |
| CNTB Connect Biopharma Holdings L | New | 0.12% | +0.12 |
| FOLD Amicus Therapeutics Inc. | New | 0.09% | +0.09 |
| UNH Unitedhealth Group Inc. | New | 0.09% | +0.09 |
| OVID Ovid Therapeutics Inc. | Add +6.0% | 0.61% | +0.09 |
Options Activity Q4 2025 → Q1 2026
| TERN Terns Pharmaceuticals Inc. | call | New | 200,000 | $10.5M |
| ABVX Abivax SA-ADR | call | New | 44,000 | $4.9M |
| AAM Aa Mission Acquisition Cor-A | call | Sold out | 405,089 | $4.3Mbefore exit |
| LQDA Liquidia Corp. | put | Add +308.2% | 100,000 | $3.8M |
| XBI SS SPDR S&P Biotech ETF | put | New | 15,000 | $1.9M |
| AQST Aquestive Therapeutics Inc. | put | Sold out | 254,000 | $1.6Mbefore exit |
| QURE Uniqure NV | call | Add +233.3% | 100,000 | $1.6M |
| GOSS Gossamer Bio Inc. | put | Sold out | 463,200 | $1.4Mbefore exit |
| OMER Omeros Corp. | put | Sold out | 75,000 | $1.3Mbefore exit |
| KPTI Karyopharm Therapeutics Inc. | call | New | 205,200 | $1.1M |
| URGN Urogen Pharma Ltd. | call | Sold out | 40,000 | $937Kbefore exit |
| REPL Replimune Group Inc. | call | Add +300.0% | 100,000 | $765K |
| FULC Fulcrum Therapeutics Inc. | call | Sold out | 65,000 | $735Kbefore exit |
| NVO Novo-Nordisk A/S-Spons ADR | call | New | 13,000 | $478K |
| CTMX Cytomx Therapeutics Inc. | call | Sold out | 100,000 | $426Kbefore exit |
| RARE Ultragenyx Pharmaceutical Inc. | call | Add +100.0% | 20,000 | $419K |
| MLTX Moonlake Immunotherapeutics | call | New | 20,000 | $373K |
| CRBP Corbus Pharmaceuticals Holdi | call | New | 35,000 | $329K |
| DYN Dyne Therapeutics Inc. | call | Sold out | 10,000 | $196Kbefore exit |
| OTLK Outlook Therapeutics Inc. | put | Sold out | 100,000 | $158Kbefore exit |
| INO Inovio Pharmaceuticals Inc. | call | Sold out | 75,500 | $131Kbefore exit |
| GOSS Gossamer Bio Inc. | call | Sold out | 35,100 | $109Kbefore exit |
| VTGN Vistagen Therapeutics Inc. | put | Sold out | 120,000 | $79Kbefore exit |
| QUINCE THERAPEUTICS INC | put | Reduce -37.5% | 50,000 | $5K |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
Notes & Other Activity Q4 2025 → Q1 2026
| BRIDGEBIO PHARMA INC (BBIO 2.25 02/01/29) | NOTE 2.250% 2/0 · principal | New | 45,000 | $4.9M |
| BRIDGEBIO PHARMA INC (BBIO 2.5 03/15/27) | NOTE 2.500% 3/1 · principal | New | 20,000 | $3.6M |
| BRIDGEBIO PHARMA INC (BBIO 1.75 03/01/31) | NOTE 1.750% 3/0 · principal | New | 30,000 | $49K |
Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 260 | $2.1B | ABVX, PTGX, ROIV, SPY, IMVT |
| Q1 2026 | 290 | $1.6B | ABVX, PTGX, ROIV, IMVT, SPY |
| Q4 2025Amended | 248 | $1.3B | ABVX, PTGX, ROIV, IMVT, RNAM |
| Q3 2025 | 196 | $1.0B | ABVX, KROS, PTGX, ROIV, BOXX |
| Q2 2025 | 192 | $609.1M | KROS, PTGX, BOXX, ZLAB, ABVX |
| Q1 2025 | 185 | $505.1M | PTGX, BOXX, ROIV, ZLAB, IMVT |
| Q4 2024 | 185 | $469.3M | ROIV, PTGX, BOXX, ZLAB, IMVT |
| Q3 2024 | 244 | $596.5M | CYTK, PTGX, BBIO, BOXX, ROIV |
| Q2 2024 | 231 | $496.6M | PTGX, CYTK, ROIV, BOXX, BBIO |
| Q1 2024 | 223 | $366.2M | BOXX, ROIV, ALNY, PTGX, CYTK |